Transcriptomic Landscape of Paclitaxel-Induced Multidrug Resistance in 3D Cultures of Colon Cancer Cell Line DLD1

Multidrug resistance (MDR) significantly contributes to colon cancer recurrence, making it essential to understand its molecular basis for improved therapies. This study aimed to identify genes and pathways involved in resistance to standard chemotherapeutics by comparing transcriptome profiles of sensitive and paclitaxel-induced MDR colonospheres. Cell viability and growth were assessed following treatment with 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, and cetuximab. Drug concentrations in culture media posttreatment were measured using high-performance liquid chromatography (HPLC). RNA sequencing (RNA-seq) of untreated sensitive and resistant colonospheres identified differentially expressed genes linked to baseline resistance. Our results confirmed cross-resistance in the resistant model, showing highest oxaliplatin tolerance may involve mechanisms beyond efflux. Transcriptome analysis highlighted upregulation of PIGR and activation of the ribosomal signaling pathway as potential resistance mediators. Notably, AKR1B10, a gene linked to chemotherapeutic detoxification, was overexpressed, whereas genes related to adhesion and membrane transport were downregulated. The overexpression of ribosomal protein genes suggests ribosome biogenesis plays a key role in acquired resistance. These findings suggest that targeting ribosome biogenesis and specific deregulated genes such as PIGR and AKR1B10 may offer promising strategies to overcome MDR in colon cancer.

• Publication year

  2025

• Venue

  International Journal of Molecular Sciences

• Publication date

  2025-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/ijms26146580PMID 40724830PMCID 12294787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinicopathological Significance of APC Mutation in Patient with Colorectal Cancer

  2025cited by this paper
• Role of protein degradation systems in colorectal cancer

  2024cited by this paper
• Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening

  2024cited by this paper
• Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis

  2024influential reference
• Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models

  2023cited by this paper
• Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells

  2023cited by this paper
• Targeting epigenetic regulators to overcome drug resistance in cancers

  2023cited by this paper
• Emerging roles of 3D-culture systems in tackling tumor drug resistance

  2023cited by this paper
• Polymeric immunoglobulin receptor (pIgR) in cancer

  2023cited by this paper
• Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review)

  2023cited by this paper
• Ribosome-Directed Therapies in Cancer

  2022cited by this paper
• Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis.

  2022cited by this paper
• Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

  2022cited by this paper
• FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells

  2022cited by this paper
• Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics

  2022cited by this paper
• Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent Chemotherapy

  2022cited by this paper
• Corrigendum: Polymeric immunoglobulin receptor suppresses colorectal cancer through the AKT-FOXO3/4 axis by downregulating LAMB3 expression

  2022cited by this paper
• Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches

  2022cited by this paper
• Extracellular Vesicles and Resistance to Anticancer Drugs: A Tumor Skeleton Key for Unhinging Chemotherapies

  2022cited by this paper
• Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

  2022cited by this paper
• TMEM189 negatively regulates the stability of ULK1 protein and cell autophagy

  2022cited by this paper
• Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance

  2022cited by this paper
• CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I

  2022cited by this paper
• Therapeutic strategies to overcome taxane resistance in cancer.

  2021cited by this paper
• The Role of AKR1B10 in Physiology and Pathophysiology

  2021cited by this paper
• A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling

  2021cited by this paper
• Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

  2021cited by this paper
• Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma

  2021cited by this paper
• Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines

  2021cited by this paper
• Comprehensive Analysis of the Expression and Prognosis for MMPs in Human Colorectal Cancer

  2021cited by this paper
• Expression and clinical significance of UBE2V1 in cervical cancer

  2021cited by this paper
• Aldo-Keto Reductases and Cancer Drug Resistance

  2021cited by this paper
• FOLFOXIRI reintroduction in metastatic colorectal cancer.

  2020cited by this paper
• High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer

  2020cited by this paper
• mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

  2020cited by this paper
• CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

  2020cited by this paper
• Parvifloron D from Plectranthus strigosus: Cytotoxicity Screening of Plectranthus spp. Extracts

  2019cited by this paper
• Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines

  2019cited by this paper
• Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure

  2019cited by this paper
• Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma

  2019influential reference
• CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells

  2019cited by this paper
• Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.

  2019cited by this paper
• Discovery of novel inhibitors of ribosome biogenesis by innovative high throughput screening strategies.

  2019cited by this paper
• Treatment of cancer cells with chemotherapeutic drugs results in profound changes in expression of genes encoding aldehyde-metabolizing enzymes

  2019cited by this paper
• Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells

  2019cited by this paper
• CLDN4 silencing promotes proliferation and reduces chemotherapy sensitivity of gastric cancer cells through activation of the PI3K/Akt signalling pathway

  2019cited by this paper
• DUOX2-mediated production of reactive oxygen species induces epithelial mesenchymal transition in 5-fluorouracil resistant human colon cancer cells

  2018cited by this paper
• Quantitative proteomic and phosphoproteomic comparison of human colon cancer DLD-1 cells differing in ploidy and chromosome stability

  2018cited by this paper
• Commonly expressed genes among cancer stem cells induced from hiPSCs and Obtained from cancer tissues or cell lines

  2018cited by this paper
• Jatrophane diterpenoids with multidrug-resistance modulating activity from the latex of Euphorbia nicaeensis.

  2018cited by this paper
• The evolution of single cell-derived colorectal cancer cell lines is dominated by the continued selection of tumor-specific genomic imbalances, despite random chromosomal instability

  2018cited by this paper
• Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel.

  2017cited by this paper
• DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P‐glycoprotein overexpressing cancer cells

  2017cited by this paper
• Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies

  2017cited by this paper
• Trends in colorectal cancer admissions and stage at presentation: impact of screening

  2016cited by this paper
• Regulation of multidrug resistance by microRNAs in anti-cancer therapy

  2016cited by this paper
• Maintenance strategy in metastatic colorectal cancer: A systematic review.

  2016cited by this paper
• Functional Analysis of an Aγ-Globin Gene Promoter Variant (HBG1: g.-225_-222delAGCA) Underlines Its Role in Increasing Fetal Hemoglobin Levels Under Erythropoietic Stress

  2016cited by this paper
• Role of Biologics in First-Line Treatment of Colorectal Cancer.

  2016cited by this paper
• Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

  2015cited by this paper
• Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.

  2015cited by this paper
• Anti-cancer effects of cerium oxide nanoparticles and its intracellular redox activity.

  2015cited by this paper
• mTORC1 signaling controls multiple steps in ribosome biogenesis.

  2014cited by this paper
• Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.

  2014cited by this paper
• Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.

  2013cited by this paper
• The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: the unique way of multi-drug resistance modulation.

  2013cited by this paper
• Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing

  2013cited by this paper
• Jatrophane diterpenoids from the latex of Euphorbia dendroides and their anti-P-glycoprotein activity in human multi-drug resistant cancer cell lines.

  2013cited by this paper
• The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.

  2011influential reference
• Involvement of the aldo–keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms

  2011cited by this paper
• Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

  2010cited by this paper
• Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.

  2009cited by this paper
• Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

  2009cited by this paper
• 5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer

  2008cited by this paper
• Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.

  2006cited by this paper
• Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.

  2004cited by this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cited by this paper
• Pharmacokinetics of oxaliplatin in humans

  2002cited by this paper
• Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.

  2000cited by this paper
• Clinical pharmacokinetics of oxaliplatin: a critical review.

  2000cited by this paper

• No citing papers are available for this paper.